You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Related Medications Videos on Diabetes Health TV
Injection Site Awareness Week
First Look: New iPhone App for Logging Readings and Much More
Easy to Use Insulin Delivery Patch
Popular Actos Articles
Highly Recommended Actos Articles
Metformin, the cornerstone in treating type 2 diabetes, saw an increase in usage among type 2s from 23 percent of that population in 1997 to 53 percent in 2012. But that increase has since plateaued due to the introduction of additional drugs that target insulin secretion and glucose regulation.
0 comments - Jan 4, 2014 -
Insulin sensitizers--drugs that increase sensitivity to insulin such as Avandia and Actos--could help lessen the risk of peripheral arterial disease (PAD) for those with type 2 diabetes, according to a new study.
1 comment - Jul 5, 2013 -
A significant majority-20 of 26 members attending a combined meeting of FDA advisory committees-has voted to modify or remove the current restrictive label and distribution regulations affecting the type 2 drug Avandia.
0 comments - Jun 9, 2013 -
The Food and Drug Administration has approved US sale of generic pioglitazone (trade name Actos) for the treatment of type 2 diabetes. Actos, originally developed and trademarked by Takeda Pharmaceuticals, works by decreasing insulin resistance in type 2 patients. The prescription drug, which belongs to the class of drugs known as thiazolidinediones (TZDs), has enjoyed great commercial success in the United States since its introduction in 1999, posting estimated sales last year of $2.7 billion.
0 comments - Aug 27, 2012 -
A recent article in the Chicago Tribune reports that patients using Lipitor, Actos, or Plavix may start enjoying savings of up to 90 percent as patents on those drugs expire. The three drugs comprise a significant percentage of the $300 billion brand-name U.S. pharmaceutical market, according to the Tribune.
2 comments - May 27, 2011 -
The U.S. Food and Drug Administration today announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.
0 comments - Sep 23, 2010 -
Scientists have identified five genetic biomarkers that predict how well a type 2 patient will respond to the drug Actos. Their work could be the first step toward a system that would allow doctors to predetermine which drugs will best help each person with diabetes.
0 comments - Jul 3, 2009 -
Results from DURATION-2, a 26-week test comparing the diabetic drugs Januvia, Actos, and experimental long-acting Byetta (Byetta LAR) show that Byetta produced lower A1c's and more weight loss than the other two drugs.
5 comments - Apr 15, 2009 -
Physicians who treat people with type 2 diabetes face difficult choices when selecting the best medical therapy for each patient. The decision process is further complicated by the fact that because type 2 diabetes is a progressive disease, therapeutic agents that were initially successful may fail five or ten years later.
151 comments - Mar 20, 2009 -
Avandia (rosiglitazone) and Actos (pioglitazone), two medications used to lower blood sugar in type 2 patients, double the risk of fractures in women, but not in men, says a new study.
0 comments - Dec 22, 2008 -
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.